Marta GarcÃ-a-Montojo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7498786/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Multiple Sclerosis Journal, 2012, 18, 1721-1736.	3.0	165
2	Human endogenous retrovirus-K (HML-2): a comprehensive review. Critical Reviews in Microbiology, 2018, 44, 715-738.	6.1	143
3	Human Herpesvirus 6 and Multiple Sclerosis: A One-Year Follow-up Study. Brain Pathology, 2006, 16, 20-27.	4.1	65
4	The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. PLoS ONE, 2013, 8, e53623.	2.5	64
5	Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. PLoS ONE, 2014, 9, e104836.	2.5	36
6	Syncytinâ€1/HERVâ€W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. European Journal of Immunology, 2020, 50, 685-694.	2.9	35
7	JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Multiple Sclerosis Journal, 2007, 13, 590-595.	3.0	30
8	Environment–gene interaction in multiple sclerosis: Human herpesvirus 6 and MHC2TA. Human Immunology, 2007, 68, 685-689.	2.4	30
9	HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV. Retrovirology, 2014, 11, 2.	2.0	30
10	Human Endogenous Retrovirus HERV-Fc1 Association with Multiple Sclerosis Susceptibility: A Meta-Analysis. PLoS ONE, 2014, 9, e90182.	2.5	29
11	Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressive. Multiple Sclerosis Journal, 2007, 13, 578-583.	3.0	28
12	Role of the Human Endogenous Retrovirus HERV-K18 in Autoimmune Disease Susceptibility: Study in the Spanish Population and Meta-Analysis. PLoS ONE, 2013, 8, e62090.	2.5	25
13	CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Multiple Sclerosis Journal, 2011, 17, 513-520.	3.0	19
14	Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab. Journal of NeuroImmune Pharmacology, 2013, 8, 1277-1286.	4.1	19
15	SMARCB1 deletion in atypical teratoid rhabdoid tumors results in human endogenous retrovirus K (HML-2) expression. Scientific Reports, 2021, 11, 12893.	3.3	17
16	Herpesvirus active replication in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 98-102.	0.6	15
17	MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. BMC Neurology, 2012, 12, 107.	1.8	14
18	Study of the antiâ€ <scp>JCV</scp> antibody levels in a Spanish multiple sclerosis cohort. European Journal of Clinical Investigation, 2017, 47, 158-166.	3.4	14

Marta GarcÃa-Montojo

#	Article	IF	CITATIONS
19	Tollâ€like receptorâ€9 in <scp>S</scp> panish multiple sclerosis patients: an association with the gender. European Journal of Neurology, 2014, 21, 537-540.	3.3	11
20	Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. European Journal of Neurology, 2016, 23, 182-189.	3.3	11
21	HERV-W envelope expression in blood leukocytes as a marker of disease severity of COVID-19. EBioMedicine, 2021, 67, 103363.	6.1	9
22	Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients. Journal of NeuroVirology, 2007, 13, 504-512.	2.1	8
23	Technical considerations in detection of HERV-K in amyotrophic lateral sclerosis: selection of controls and the perils of qPCR. Acta Neuropathologica Communications, 2019, 7, 101.	5.2	8
24	Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2022, 19, 1085-1101.	4.4	8
25	Role of maternal corticosterone in the development and maturation of the aminoacidergic systems of the rat brain. International Journal of Developmental Neuroscience, 2007, 25, 465-471.	1.6	6
26	Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid. Clinical Neuropharmacology, 2017, 40, 29-33.	0.7	6
27	Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion. BBA Clinical, 2015, 3, 162-167.	4.1	4
28	Re: Errors in the Editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670–1672]. Multiple Sclerosis Journal, 2013, 19, 831-832.	3.0	0